Merck & Co. dividend track record, shares in focus on the NYSE

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 13:25.

Merck & Co., Inc. (US58933Y1055) remains one of the established U.S. large-cap pharmaceutical names for income-focused investors. The company is listed on the NYSE, where it sits alongside peers such as Pfizer and Bristol Myers Squibb in the U.S. pharma cohort.

What recent analyst views show

Analyst coverage for Merck & Co., Inc. stays broad, with major houses like Goldman Sachs, Morgan Stanley and JPMorgan regularly updating their models for the U.S. pharmaceutical sector. On MarketScreener, a significant majority of analysts currently rate Merck stock at Buy or Outperform, while only a small minority sit at Hold or Sell, reflecting a supportive consensus backdrop for the shares.

The aggregated analyst price targets suggest modest upside from current trading levels, according to the consensus data presented on MarketScreener and similar platforms that compile Wall Street expectations. Many of these models focus on the companys oncology franchise and its large immuno-oncology drug Keytruda, which has become one of the best-selling cancer therapies globally and a central driver in revenue projections for the coming years.

How Merck compares with large pharma peers

Within the global pharmaceutical space, investors often compare Merck & Co., Inc. with U.S. peers such as Pfizer, Bristol Myers Squibb and Johnson & Johnson as well as European players like Novartis and Roche. Merck has distinguished itself in recent years with strong growth in oncology, particularly through Keytruda, while peers have relied more on vaccines, cardiovascular drugs or broader diversified portfolios.

In sector terms, Merck is commonly grouped in the health care and pharmaceuticals category, where valuation metrics like forward price-to-earnings ratios and dividend yields help investors differentiate among competing stocks. Based on recent data from major finance portals such as Yahoo Finance and the companys own filings, Merck trades at a valuation that investors tend to see as reflecting its robust oncology franchise and pipeline, balanced against the inevitable long-term patent expiry considerations.

The product behind the stock

Merck & Co., Inc. generates a large share of its revenue from its oncology drug Keytruda, a PD-1 inhibitor used across multiple cancer types including melanoma, non-small cell lung cancer and head and neck cancer. This blockbuster medicine, alongside other prescription pharmaceuticals and vaccines, underpins the companys cash flows and supports its ongoing dividend payments.

Where the stock trades today

Merck & Co., Inc. shares trade on the NYSE under the ticker MRK, quoted in U.S. dollars, with the stock forming part of the large-cap U.S. health care segment.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.